Talent mobility in multinational pharmaceutical companies is accelerating, and former Novartis executives will join Boehringer Ingelheim

Since the departure of Mehdi Shahidi, MD, in February, Boehringer Ingelheim has been looking for a new chief medical officer (CMO).

Recently, former Novartis executive Lykke Hinsch Gylvin said that she will join Boehringer Ingelheim as CMO and global head of
medicine.
It is understood that the new CMO Lykke Hinsch Gylvin previously served at Novartis as vice president of global medical franchise and head of
neuroscience.
Prior to that, she spent four years at AstraZeneca and also held leadership positions
at Roche, Novo Nordisk and Lundbeck.
It is understood that personnel changes in multinational enterprises have been frequent
in recent years.
In the past month, many multinational pharmaceutical companies, including Merck and GSK, have reported the news
of executive changes.
Among them, it is worth noting that behind the frequent changes in the executives of multinational pharmaceutical companies, the flow of talents before each other is also intensifying
.
At the end of October, Novartis announced that Tian Yu will join Novartis on November 10, 2022, as the head of immunotherapy for Novartis Innovative Drugs in China, based in
Shanghai.
He will be a member of the management team of Innovative Drugs China and will report directly to Ying Zhang
, President of Novartis Innovative Drugs China.
According to public information, before joining Novartis, Tian Yu was the head of Merck's China Oncology Business Unit, and successfully led KEYTRUDA's self-funded market strategy
.
Prior to joining Merck China, she also served as the Head of
Solid Tumor Disease at Novartis Oncology China.
In addition to the frequent executive turnover between multinational pharmaceutical companies, in recent years, more and more multinational pharmaceutical executives and overseas talents have increasingly intersected with local biotech companies in China
.
On October 19, Sihe Gene released news announcing that Huang Yue, former head of translational medicine at Merck in China, officially joined Sihe Genomics as the chief translational science officer (CTO), fully responsible for the preclinical and clinical research and development of
Sihe Gene independent innovation antisense oligonucleic acid drug research and development project.
Sihe Gene is a biotechnology company just established last year, focusing on antisense oligonucleic acid technology, and currently has multiple pipelines for metabolism, tumors, central nervous system diseases and other pipelines are being promoted
.
In September, Luo Yongqing became the Chief Executive Officer and Executive Director of
Genting Sunshine.
Previously, he served as Global Vice President and General Manager
of Gilead Sciences.
In August, Tengsheng Biopharma announced Eleanor (Ellee) de Groot as Senior Vice President and Chief Technology Officer and Aleksandar Skuban as Head of
Central Nervous System Disease Therapeutics.
It is reported that both executives have many years of overseas experience
.
.
.
.
.
.
.
In general, at a time when the policy environment of the pharmaceutical industry is intensifying and market competition is becoming increasingly fierce, the flow of talents in domestic and foreign pharmaceutical rivers and lakes has accelerated and has become the
norm.
In this context, how to retain talents, consolidate the foundation of pharmaceutical talents, and improve the overall level of medical education will become a problem
that pharmaceutical companies need to constantly think about and accelerate to solve.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.